{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:00Z","timestamp":1793730960407,"version":"4.6.1"},"reference-count":146,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/14737140.2025.2570163","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:40:48Z","timestamp":1759423248000},"page":"1391-1404","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies"],"prefix":"10.1080","volume":"25","author":[{"given":"Wilson M.","family":"Alobuia","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center","place":["Columbus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center","place":["Columbus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800788"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X20925045"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.131"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112641"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-04966-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.06.002"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.01.001"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.1999809"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.5137"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.020"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28312"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174320"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2017.03.001"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_4_18_1","unstructured":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer | NEJM evidence [Internet]. [cited 2025 May 18]. Available from: https:\/\/evidence.nejm.org\/doi\/full\/10.1056\/EVIDoa2200015"},{"key":"e_1_3_4_19_1","unstructured":"Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for biliary tract cancers V.1.2025. \u00a9 National Comprehensive Cancer Network Inc. 2025. All rights reserved. [Accessed 2025 May 16]. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2310196"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000743"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0987-3"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.11.005"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31942"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32803"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2013.10.004"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.05.017"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.008"},{"issue":"1","key":"e_1_3_4_30_1","first-page":"19","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan SA","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int Off J Int Assoc Study Liver. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.08.18"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.09.01"},{"key":"e_1_3_4_33_1","unstructured":"Biliary cancer: utility of next\u2010generation sequencing for clinical management - Javle - 2016 - Cancer - Wiley Online Library [Internet]. [cited 2025 May 18]. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30254"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.030"},{"key":"e_1_3_4_36_1","unstructured":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre open-label single-arm phase 2 study - ScienceDirect [Internet]. [cited 2025 May 18]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2468125321001965"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.011"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1834"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2259802"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2036"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488"},{"key":"e_1_3_4_44_1","unstructured":"Fight-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements - PMC [Internet]. [cited 2025 May 18]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9892961\/"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0182"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1042"},{"key":"e_1_3_4_47_1","unstructured":"Taiho Oncology Inc. A phase 3 open-label randomized study of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced cholangiocarcinoma harboring FGFR2 gene rearrangements FOENIX-CCA3 [Internet]. clinicaltrials.gov. 2025 [cited 2025 May 23]. Report No.: NCT04093362. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04093362"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"e_1_3_4_49_1","unstructured":"Helsinn Healthcare SA. Withdrawal of approval of new drug application for TRUSELTIQ (infigratinib phosphate) capsules 25 milligrams and 100 milligrams [internet]. Fed. Regist. 2024 [cited 2025 May 22]. Available from: https:\/\/www.federalregister.gov\/documents\/2024\/05\/16\/2024-10714\/helsinn-healthcare-sa-withdrawal-of-approval-of-new-drug-application-for-truseltiq-infigratinib"},{"key":"e_1_3_4_50_1","unstructured":"Research C for DE and. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. FDA [Internet]. 2019 [cited 2025 May 23]."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00275-9"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.610"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317756121"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad338"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16224"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100356"},{"key":"e_1_3_4_59_1","unstructured":"Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial - PubMed [Internet]. [cited 2025 Jul 12]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39917990\/"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"e_1_3_4_61_1","unstructured":"Research C for DE and. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. FDA [Internet]. 2024 [cited 2025 Jun 25]."},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.018"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3597"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00434"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020768"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon2571"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002663"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36399-y"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00223"},{"key":"e_1_3_4_71_1","unstructured":"Research C for DE and. FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer. FDA [Internet]. 2024 [cited 2025 Jun 25]."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115432"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02010"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_4_80_1","unstructured":"Research C for DE and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA [Internet]. 2024 [cited 2025 Jun 26]."},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01711-w"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.321"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-338"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00150-X"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00606"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820983013"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1926"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1476"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.706"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.07.026"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.5679"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2024.06.027"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0368"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01839-y"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/23808993.2021.1910023"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz383"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0324-7"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100351"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy279.397"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.2106"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.013"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03323-w"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70243"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13039-024-00698-w"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6786"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3858-3_11"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01839-x"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.045"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168675"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81392-0"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.12.006"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.24622"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001439"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020271"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1317"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102627"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1916912"},{"issue":"1","key":"e_1_3_4_120_1","first-page":"43","article-title":"Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance","volume":"39","author":"Fouassier L","year":"2019","unstructured":"Fouassier L, Marzioni M, Afonso MB, et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int Off J Int Assoc Study Liver. 2019;39(Suppl 1):43\u201362.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2034785"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.019"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13121"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.061"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00304-5"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0877"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73581-8"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1286"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15812"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-012-0542-6"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.12.031"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193180"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01227-6"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00429-9"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00473-5"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072105"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2024.15.8.2"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2658"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174405"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260180"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04613-6"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1733528"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2319317"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03548-2"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.877194"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.041"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.005"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2020.02.02"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2570163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:06:02Z","timestamp":1764057962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2570163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":146,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/14737140.2025.2570163"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2570163","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}